Condition: Advanced Endometrial Cancer · Sponsor: 3D Medicines (Sichuan) Co., Ltd.
This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.
This description comes directly from the study's public registry record.
bin She · 15973143911 · bin.she@3d-medicines.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing University Three Gorges Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-Sen Memorial Hospital | Guangzhou, Guangdong, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Wuhan Union Hospital of China | Wuhan, Hubei, China | Recruiting |
| :Hubei Cancer Hospital | Wuhan, Hubei, China | Recruiting |
| The Second Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| Yueyang Center Hospital | Yueyang, Hunan, China | Recruiting |
| :Nanjing Maternity and Child Health Care Hospital | Nanjing, Jiangsu, China | Recruiting |
| Ganzhou Cancer Hospital | Ganzhou, Jiangxi, China | Recruiting |
| Liaoning Cancer Hospital | Shenyang, Liaoning, China | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05112991